Moreover, insulinresistance, hyperinsulinemia, hyperglycemia, and chronic inflammationare the mechanisms of T2D-associated cancer occurrence and progression.3 Despite the large panel of treatment optionsfor T2D, including insulin analogues, biguanides, meglitinides, sodium-glucosecotransporter-2 inhibitors, incretin-based therapies, dipeptidyl peptidase4, α-glucosidase inhibitors, thiazolidinediones, and sulfonylureas,currently available therapies cause side effects and none of themhave shown promise in halting the underlying causes of T2D, namely,insulin resistance.4 Here, INS is linked to Insulin resistance.